

Vincenzo Messina

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7814506/publications.pdf>

Version: 2024-02-01

77
papers

2,574
citations

201575

27
h-index

197736

49
g-index

78
all docs

78
docs citations

78
times ranked

3322
citing authors

#	ARTICLE	IF	CITATIONS
1	Outcomes in Patients With Hyperglycemia Affected by COVID-19: Can We Do More on Glycemic Control?. <i>Diabetes Care</i> , 2020, 43, 1408-1415.	4.3	341
2	Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. <i>Journal of Hepatology</i> , 2012, 56, 1006-1011.	1.8	155
3	HBV superinfection in hepatitis C virus chronic carriers, viral interaction, and clinical course. <i>Hepatology</i> , 2002, 36, 1285-1291.	3.6	122
4	Randomised study comparing 48 and 96 weeks peginterferon α -2a therapy in genotype D HBeAg-negative chronic hepatitis B. <i>Gut</i> , 2013, 62, 290-298.	6.1	105
5	Negative impact of hyperglycaemia on tocilizumab therapy in Covid-19 patients. <i>Diabetes and Metabolism</i> , 2020, 46, 403-405.	1.4	105
6	The importance of HCV on the burden of chronic liver disease in Italy: A multicenter prevalence study of 9,997 cases. <i>Journal of Medical Virology</i> , 2005, 75, 522-527.	2.5	102
7	HBV superinfection in HCV chronic carriers: A disease that is frequently severe but associated with the eradication of HCV. <i>Hepatology</i> , 2009, 49, 1090-1097.	3.6	94
8	Does poor glycaemic control affect the immunogenicity of the COVID-19 vaccination in patients with type 2 diabetes: The CAVEAT study. <i>Diabetes, Obesity and Metabolism</i> , 2022, 24, 160-165.	2.2	75
9	Hyperglycaemia on admission to hospital and COVID-19. <i>Diabetologia</i> , 2020, 63, 2486-2487.	2.9	72
10	Liver microRNA hsa-miR-125a-5p in HBV Chronic Infection: Correlation with HBV Replication and Disease Progression. <i>PLoS ONE</i> , 2013, 8, e65336.	1.1	72
11	Could Anti-Hypertensive Drug Therapy Affect the Clinical Prognosis of Hypertensive Patients With COVID-19 Infection? Data From Centers of Southern Italy. <i>Journal of the American Heart Association</i> , 2020, 9, e016948.	1.6	69
12	Reactivation of overt and occult hepatitis B infection in various immunosuppressive settings. <i>Journal of Medical Virology</i> , 2011, 83, 1909-1916.	2.5	64
13	Diagnosis and clinical impact of occult hepatitis B infection in patients with biopsy proven chronic hepatitis C: A multicenter study. <i>Journal of Medical Virology</i> , 2008, 80, 1547-1553.	2.5	63
14	The epidemiology of hepatitis delta infection in Italy. <i>Journal of Hepatology</i> , 1992, 15, 211-215.	1.8	62
15	Evolving clinical landscape of chronic hepatitis B: A multicenter Italian study. <i>Journal of Medical Virology</i> , 2009, 81, 1999-2006.	2.5	61
16	Chronic Hepatitis B in Italy: New Features of an Old Disease--Approaching the Universal Prevalence of Hepatitis B e Antigen-Negative Cases and the Eradication of Hepatitis D Infection. <i>Clinical Infectious Diseases</i> , 2008, 46, 110-113.	2.9	60
17	Treatment of chronic hepatitis B: Recommendations from an Italian workshop. <i>Digestive and Liver Disease</i> , 2008, 40, 603-617.	0.4	50
18	Prevention of hepatitis C in Italy: lessons from surveillance of type-specific acute viral hepatitis. <i>Journal of Viral Hepatitis</i> , 2000, 7, 30-35.	1.0	47

#	ARTICLE	IF	CITATIONS
19	Clinical Presentation, Outcome, and Response to Therapy Among Patients With Acute Exacerbation of Chronic Hepatitis C. <i>Clinical Gastroenterology and Hepatology</i> , 2013, 11, 1174-1180.e11.	2.4	47
20	Implications of ABO blood group in hypertensive patients with covid-19. <i>BMC Cardiovascular Disorders</i> , 2020, 20, 373.	0.7	46
21	Improvement in the aetiological diagnosis of acute hepatitis C: A diagnostic protocol based on the anti-HCV-IgM titre and IgG Avidity Index. <i>Journal of Clinical Virology</i> , 2009, 46, 222-229.	1.6	42
22	Anti-HCV IgG avidity index in acute hepatitis C. <i>Journal of Clinical Virology</i> , 2007, 40, 110-115.	1.6	40
23	Acute hepatitis C: A 24-week course of pegylated interferon alpha-2b versus a 12-week course of pegylated interferon alpha-2b alone or with ribavirin. <i>Hepatology</i> , 2014, 59, 2101-2109.	3.6	38
24	Glycaemic control is associated with SARS-CoV-2 breakthrough infections in vaccinated patients with type 2 diabetes. <i>Nature Communications</i> , 2022, 13, 2318.	5.8	33
25	Diagnosis of hepatitis C virus related acute hepatitis by serial determination of IgM anti-HCV titres. <i>Journal of Hepatology</i> , 2005, 42, 646-651.	1.8	32
26	Real-life glecaprevir/pibrentasvir in a large cohort of patients with hepatitis C virus infection: The MISTRAL study. <i>Liver International</i> , 2019, 39, 1852-1859.	1.9	31
27	Factors affecting the changes in molecular epidemiology of acute hepatitis B in a Southern Italian area. <i>Journal of Viral Hepatitis</i> , 2009, 17, 493-500.	1.0	30
28	Lamivudine-resistant HBV strain rtM204V/I in acute hepatitis B. <i>Journal of Infection</i> , 2013, 67, 322-328.	1.7	26
29	The aetiology of chronic hepatitis in Italy: results from a multicentre national study. <i>Digestive and Liver Disease</i> , 2004, 36, 829-833.	0.4	24
30	HCV infection is a risk factor for gallstone disease in liver cirrhosis: an Italian epidemiological survey. <i>Journal of Viral Hepatitis</i> , 2007, 14, 618-623.	1.0	24
31	Clinical and virological characteristics associated with severe acute hepatitis B. <i>Clinical Microbiology and Infection</i> , 2014, 20, O991-O997.	2.8	23
32	Autonomic nervous system and lipid metabolism: findings in anxious-depressive spectrum and eating disorders. <i>Lipids in Health and Disease</i> , 2011, 10, 192.	1.2	22
33	More Severe COVID-19 in Patients With Active Cancer: Results of a Multicenter Cohort Study. <i>Frontiers in Oncology</i> , 2021, 11, 662746.	1.3	21
34	Antiarrhythmic Drug Therapy after Radiofrequency Catheter Ablation in Patients with Atrial Fibrillation. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2007, 30, S112-5.	0.5	20
35	HCV clearance after direct-acting antivirals in patients with cirrhosis by stages of liver impairment: The ITAL-C network study. <i>Digestive and Liver Disease</i> , 2017, 49, 1022-1028.	0.4	19
36	Adherence to Barcelona Clinic Liver Cancer guidelines in field practice: Results of Progetto Epatocarcinoma Campania. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 1123-1130.	1.4	18

#	ARTICLE	IF	CITATIONS
37	Interferon-Free Regimens in Hepatitis B Surface Antigen/Anti-Hepatitis C Virus Positive Patients: The Need to Control Hepatitis B Virus Replication to Avoid Hepatitis B Virus Reactivation. <i>Clinical Gastroenterology and Hepatology</i> , 2017, 15, 1800-1802.	2.4	17
38	Tolerability and efficacy of anti-HBV nucleos(t)ide analogues in HBV-DNA-positive cirrhotic patients with HBV/HCV dual infection. <i>Journal of Viral Hepatitis</i> , 2012, 19, 890-896.	1.0	15
39	Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study. <i>The Lancet Gastroenterology and Hepatology</i> , 2017, 2, 427-434.	3.7	15
40	Characteristics of HCV positive subjects referring to hospitals in Italy: a multicentre prevalence study on 6 999 cases. <i>Journal of Viral Hepatitis</i> , 2006, 13, 351-354.	1.0	14
41	Virological patterns of HCV patients with failure to interferon-free regimens. <i>Journal of Medical Virology</i> , 2018, 90, 942-950.	2.5	14
42	Innovative procedures for micro-elimination of HCV infection in persons who use drugs. <i>Journal of Viral Hepatitis</i> , 2020, 27, 1437-1443.	1.0	14
43	Efficacy and safety of sofosbuvir/simeprevir plus flat dose ribavirin in genotype 1 elderly cirrhotic patients: A real-life study. <i>Liver International</i> , 2017, 37, 653-661.	1.9	13
44	Influence of antiviral therapy on the liver stiffness in chronic HBV hepatitis. <i>Infection</i> , 2018, 46, 231-238.	2.3	13
45	Editorial - Sofosbuvir/Velpatasvir as a combination with strong potential activity against SARS-CoV2 (COVID-19) infection: how to use direct-acting antivirals as broad-spectrum antiviral agents. <i>European Review for Medical and Pharmacological Sciences</i> , 2020, 24, 5193-5194.	0.5	13
46	Pegylated interferon α plus ribavirin for the treatment of chronic hepatitis C: A multicentre independent study supported by the Italian Drug Agency. <i>Digestive and Liver Disease</i> , 2014, 46, 826-832.	0.4	12
47	ITPase Activity Modulates the Severity of Anaemia in HCV-Related Cirrhosis Treated with Ribavirin-Containing Interferon-Free Regimens. <i>Antiviral Therapy</i> , 2017, 22, 551-558.	0.6	12
48	A different perspective on sofosbuvir/ledipasvir treatment of patients with HCV genotype 1b cirrhosis: The Italian network study. <i>Journal of Viral Hepatitis</i> , 2018, 25, 56-62.	1.0	11
49	Chronic hepatitis B virus infection in Italy during the twenty-first century: an updated survey in 2019. <i>European Journal of Clinical Microbiology and Infectious Diseases</i> , 2021, 40, 607-614.	1.3	10
50	Factors affecting long-term changes of liver stiffness in direct-acting anti-hepatitis C virus therapy: A multicentre prospective study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 26-34.	1.0	10
51	Correlation Between the Hepatic Expression of Human MicroRNA hsa-miR-125a-5p and the Progression of Fibrosis in Patients With Overt and Occult HBV Infection. <i>Frontiers in Immunology</i> , 2018, 9, 1334.	2.2	9
52	Effectiveness and safety of switching to entecavir hepatitis B patients developing kidney dysfunction during tenofovir. <i>Liver International</i> , 2019, 39, 484-493.	1.9	9
53	High Efficacy and Safety of Flat-Dose Ribavirin Plus Sofosbuvir/Daclatasvir in Genotype 3 Cirrhotic Patients. <i>Gut and Liver</i> , 2020, 14, 357-367.	1.4	9
54	Hepatitis C virus (HCV) micro-elimination in the hospital setting: The results of the HCV Caserta hospital project. <i>Journal of Infection and Public Health</i> , 2022, 15, 562-565.	1.9	8

#	ARTICLE	IF	CITATIONS
55	Long-term lymphoblastoid interferon- β therapy for non-cirrhotic chronic hepatitis C: an Italian multicentre study on dose and duration of IFN β treatment. <i>Research in Virology</i> , 1998, 149, 283-291.	0.7	7
56	Long-Term Results of Hybrid Therapy in Patients with Atrial Fibrillation Who Develop Atrial Flutter During Flecainide Infusion. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2005, 28, S124-S127.	0.5	7
57	Long term nucleotide and nucleoside analogs treatment in chronic hepatitis B HBeAg negative genotype D patients and risk for hepatocellular carcinoma. <i>Annals of Hepatology</i> , 2014, 13, 376-385.	0.6	7
58	Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis. <i>Infection</i> , 2018, 46, 607-615.	2.3	7
59	Epidemiology of HCV and HBV in a High Endemic Area of Southern Italy: Opportunities from the COVID-19 Pandemic? Standardized National Screening or One Tailored to Local Epidemiology?. <i>Biology</i> , 2022, 11, 609.	1.3	7
60	Epidemiology and treatment of mood disorders in a day hospital setting from 1996 to 2007: an Italian study. <i>Neuropsychiatric Disease and Treatment</i> , 2013, 9, 169.	1.0	6
61	Hepatitis C Virus Clearance in Older Adults. <i>Journal of the American Geriatrics Society</i> , 2018, 66, 85-91.	1.3	6
62	Directly Acting Antiviral-Based Treatment for HCV-Infected Persons Who Inject Drugs: A Multicenter Real-Life Study. <i>Life</i> , 2021, 11, 17.	1.1	6
63	Patients with HCV genotype-1 who have failed a direct-acting antiviral regimen: virological characteristics and efficacy of retreatment. <i>Antiviral Therapy</i> , 2019, 24, 485-493.	0.6	5
64	Factors Enhancing Treatment of Hepatitis C Virus-Infected Italian People Who Use Drugs: The CLEO-GRECAS Experience. <i>American Journal of Gastroenterology</i> , 2021, 116, 1248-1255.	0.2	5
65	Non responders to interferon therapy among chronic hepatitis patients infected with hepatitis C virus. , 1993, 8, 257-263.		5
66	Abstract 221: Exosomal MicroRNAs Drive Tromboembolism in Covid-19. <i>Circulation</i> , 2020, 142, .	1.6	5
67	Boceprevir or telaprevir in hepatitis C virus chronic infection: The Italian real life experience. <i>World Journal of Hepatology</i> , 2016, 8, 949.	0.8	5
68	Optimization of direct anti-viral agent treatment schedule: Focus on HCV genotype 3. <i>United European Gastroenterology Journal</i> , 2018, 6, 225-237.	1.6	4
69	Dangerous liaisons? The role of inflammation and comorbidities in HIV and SARS-CoV-2 infection. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 201-208.	1.3	4
70	Virological patterns of hepatitis C virus patients with failure to the current-generation direct-acting antivirals. <i>International Journal of Antimicrobial Agents</i> , 2020, 56, 106067.	1.1	3
71	Improvement of health-related quality of life and psychological well-being after HCV eradication with direct-acting antiviral agents. Real life setting data of an Italian cohort valued by Hepatitis Quality of Life Questionnaire (HQLQv2). <i>Anesthesia, Intensive Care and Pain in Neonates and Children</i> , 2020, 8, 9450.	2.4	3
72	Clinical Features of Patients with Home Isolation Sars-Cov-2 Infection: A Multicenter Retrospective Study in Southern Italy. <i>Life</i> , 2021, 11, 347.	1.1	3

#	ARTICLE	IF	CITATIONS
73	Efficacy of Unsupervised Self-Collected Mid-Turbinate FLOQSwabs for the Diagnosis of Coronavirus Disease 2019 (COVID-19). <i>Viruses</i> , 2021, 13, 1663.	1.5	3
74	THU-122-Sofosbuvir/velpatasvir ± ribavirin for retreatment of patients with chronic hepatitis C virus infection and advanced fibrosis failing to a previous DAA combination regimen. <i>Journal of Hepatology</i> , 2019, 70, e212-e213.	1.8	1
75	Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life “Liver Network Activity” (LINA) cohort update results. <i>Expert Review of Gastroenterology and Hepatology</i> , 2021, 15, 1057-1063.	1.4	1
76	HBV superinfection in HCV chronic carriers. <i>Journal of Hepatology</i> , 2002, 36, 246.	1.8	0
77	THU0289...PERSISTENCE OF CIRCULATING CRYOGLOBULINS AND RELATED SYMPTOMS AFTER HEPATITIS C VIRUS ERADICATION IN PATIENTS WITH MIXED CRYOGLOBULIN SYNDROME. , 2019, , .		0